Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

DISEASE CHARACTERISTICS:

* Histologically confirmed hematologic malignancies:

  * Chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL)

    * Absolute lymphocytosis of \> 5,000/μL
    * Lymphocytes must appear morphologically mature with \< 55% prolymphocytes (CLL)

      * Patients with \> 55% prolymphocytes are considered as having PLL
    * Lymphocyte phenotype with expression of CD20, CD19, and CD5 (CLL)
  * Non-Hodgkin lymphoma

    * Any WHO classification of histologic subtype
    * Core biopsies acceptable for primary diagnosis and immunophenotyping
    * Bone marrow biopsies as sole means of diagnosis not allowed for follicular lymphoma
  * Hodgkin lymphoma

    * Any WHO classification of histologic subtype
    * Core biopsies acceptable for primary diagnosis and immunophenotyping
    * Bone marrow biopsy is required
  * Multiple myeloma

    * Patients must have active disease requiring treatment (Durie-Salmon stage I-III)
  * Acute myeloid leukemia

    * Must have \< 10% bone marrow blasts and no circulating blasts
  * Myelodysplastic syndrome (MDS)

    * MDS as define by WHO criteria
    * Must have \< 10% marrow blasts
* Relapsed or progressive disease or myelodysplasia ≥ 6 months after prior high-dose chemotherapy with autologous hematopoietic cell support

  * Prior syngeneic transplantation allowed
* Healthy donor meeting one of the following criteria:

  * HLA-identical sibling (6/6)

    * Serologic typing for class I (A, B) and molecular typing for class II (DRB1) required
  * 8/8 matched-unrelated donor

    * Molecular identity at HLA A, B, C, and DRB1 by high-resolution typing required
  * No syngeneic donors

PATIENT CHARACTERISTICS:

* Creatinine clearance ≥ 40 mL/min
* Total bilirubin ≤ 2 mg/dL
* AST ≤ 3 times upper limit of normal
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* DLCO ≥ 40% with no symptomatic pulmonary disease
* LVEF ≥ 30% by MUGA or ECHO
* No uncontrolled diabetes mellitus or active serious infection
* No known hypersensitivity to E.coli-derived products
* No HIV infection

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 4 weeks should elapse between prior standard cytotoxic chemotherapy, radiation therapy, or surgery and the planned start of the preparative regimen on day -7